常染色体显性多囊肾病（ADPKD）是导致遗传性肾衰竭的主要病因之一，目前仍缺乏有效的手段来逆转其疾病进展。干细胞疗法因其在组织修复和免疫调节方面的潜力，成为研究的热点领域。本研究系统阐述了造血干细胞（HSCs）通过旁分泌作用、代谢重塑及免疫调控干预ADPKD病理进程的机制，并总结了其在急性肾损伤和慢性肾病中的临床转化证据。此外，文章比较分析了间充质干细胞（MSCs）和诱导多能干细胞（iPSCs）在ADPKD治疗中的独特优势与面临的挑战，为多模态干细胞疗法的开发提供理论支持。

    Autosomal dominant polycystic kidney disease（ADPKD）stands as a leading cause of inherited renal failure，with current therapeutic strategies lacking effective means to reverse disease progression．Stem cell therapy，owing to its potential in tissue repair and immunomodulation，has emerged as a focal point of research．This review systematically elucidates the mechanisms by which hematopoietic stem cells（HSCs）intervene in ADPKD pathology through paracrine effects，metabolic reprogramming，and immune regulation．Furthermore，it summarizes clinical translational evidence of HSCs in both acute kidney injury and chronic kidney disease．This article also comparatively analyzes the unique advantages and challenges of mesenchymal stem cells（MSCs）and induced pluripotent stem cells（iPSCs）in the context of ADPKD treatment，thereby providing theoretical support for the development of multimodal stem cell therapies．